These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12800452)

  • 1. Aggressive lipid-lowering therapy in high-risk groups: warranted or excessive?
    Wierzbicki AS
    Int J Clin Pract; 2003 May; 57(4):256-7. PubMed ID: 12800452
    [No Abstract]   [Full Text] [Related]  

  • 2. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
    Ballantyne CM
    Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease.
    Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM
    Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: missing the target with lipid-lowering therapy.
    Hunninghake DB; McKenney JM
    Am J Manag Care; 2000 Nov; 6(19 Suppl):S992-6. PubMed ID: 11187370
    [No Abstract]   [Full Text] [Related]  

  • 11. [New results in the management of hypercholesterolemia].
    Sármán B
    Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
    MMW Fortschr Med; 2005 Mar; 147(12):4. PubMed ID: 15832778
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic lifestyle changes and drug treatment for high blood cholesterol in China and application of the Adult Treatment Panel III guidelines.
    Muntner P; Gu D; Reynolds RF; Wu X; Chen J; Whelton PK; He J
    Am J Cardiol; 2005 Nov; 96(9):1260-5. PubMed ID: 16253594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
    MMW Fortschr Med; 2003 Dec; 145(49):57. PubMed ID: 14963997
    [No Abstract]   [Full Text] [Related]  

  • 16. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
    Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 19. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 20. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.